Tempest Therapeutics loses three board directors in single-day mass resignation

Filed May 22, 2026 · Period ending May 22, 2026 · ~1 min read

Key Changes

• high

  Stephen Brady, Michael Raab, and Christine Pellizzari all resigned from the board on May 22, 2026, with no stated disagreement. Simultaneous departures of multiple directors often signal governance upheaval or strategic pivots.

  Item 5.02 verify on EDGAR →
• medium

  All three departing directors waived their accrued and unpaid retainer fees, suggesting either cash constraints at the company or negotiated exit terms. This reduces immediate cash obligations.

  Separation Agreements verify on EDGAR →
• low

  Departing directors retain their stock options and shares, with indemnification protection continuing for six years post-separation, which is standard practice for former board members.

  Separation Agreements verify on EDGAR →